LuciRepo Repotrectinib

Repotrectinib capsules represent a new generation of potent ROS1/TRK tyrosine kinase inhibitors, specifically designed to overcome drug resistance. Its compact molecular structure effectively targets various resistance mutations—such as ROS1 G2032R—that are responsible for the failure of existing TKI therapies. For treatment-naïve patients with ROS1-positive lung cancer, the drug demonstrates exceptional objective response rates and depth of response. Furthermore, it is the first agent approved for NTRK-positive solid tumors that remains effective even after disease progression following prior TKI treatment; this provides a valuable subsequent treatment option for patients with acquired resistance, thereby realizing a dual value proposition: serving as a "breakthrough option in later lines" while simultaneously standing as a "preferred choice in the frontline setting."

Product Name

Generic Name: Repotrectinib Capsules

Brand Names: Augtyro, Aokaile, LuciRepo

English Name:Repotrectinib

Specification:40 mg/capsule; 60 capsules/bottle

Dosage Form: Oral capsules

Manufacturer: Lucius Pharmaceuticals (Laos) Co., Ltd.

National Drug Approval Number: 02 L 1071/24

Pharmacological Action

Mechanism of Action: Repotrectinib is a next-generation, potent tyrosine kinase inhibitor (TKI) that primarily targets the ROS1 proto-oncogene and NTRK genes. It possesses a unique, compact macrocyclic structure that enables efficient binding to ATP-binding sites. It maintains potent inhibitory activity even in the presence of resistance-associated mutations (such as ROS1 G2032R, SOL-1 G1951A, and NTRK GKM1R, GKPR, etc.), thereby overcoming resistance to earlier-generation TKI drugs.

Pharmacodynamics: In tumors harboring ROS1 or NTRK gene fusions, it effectively inhibits tumor cell proliferation and induces apoptosis.

Indications

1. ROS1-Positive Lung Cancer: Indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

As first-line therapy (treatment-naïve).

For patients who have previously received ROS1 TKI therapy (regardless of whether they have received platinum-based chemotherapy).

2. NTRK-Positive Solid Tumors:** Indicated for the treatment of adult and pediatric patients (aged 12 years and older) with locally advanced or metastatic solid tumors who harbor an NTRK gene fusion, have previously received TRK inhibitor therapy, and have no satisfactory alternative treatment options.

Dosage and Administration

Standard Dosage: Initial Dose (first 14 days): 160 mg orally once daily.

Maintenance Dose (after 14 days): Increase to 160 mg orally once daily.

Administration Method: May be taken with or without food. Capsules should be swallowed whole; do not chew, crush, or open the capsules. Dosage Adjustment: In the event of severe adverse reactions (e.g., hyperuricemia, neurological toxicity, etc.), treatment should be temporarily suspended, the dosage reduced, or the drug permanently discontinued, depending on the severity of the reaction.

Adverse Reactions

Common adverse reactions include:

Neurological Toxicity: Dizziness (very common), dysgeusia (taste disturbance), ataxia, peripheral neuropathy.

Laboratory Abnormalities: Elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), elevated creatinine, hyperuricemia.

Respiratory System: Dyspnea (shortness of breath), interstitial lung disease/pneumonia (requiring high vigilance).

Other: Fatigue, constipation, edema, cognitive impairment, visual impairment, etc.

Contraindications

Contraindicated in patients with a history of severe hypersensitivity to any component of this drug.

Precautions

1. Central Nervous System (CNS) Effects: May cause severe dizziness and ataxia, which can impair the ability to drive or operate machinery. Patients should be informed of this risk and exercise caution.

2. Interstitial Lung Disease (ILD)/Pneumonia: Severe, life-threatening, or fatal ILD/pneumonia may occur. Patients should be closely monitored for pulmonary symptoms during treatment; if new or worsening dyspnea, cough, fever, or other respiratory symptoms develop, the drug should be immediately discontinued and the patient evaluated.

3. Hepatotoxicity: May cause elevations in liver enzymes. Liver function should be monitored periodically during treatment.

4. Hyperuricemia: Common; may lead to gouty arthritis. Blood uric acid levels should be monitored, and uric acid-lowering therapy administered if necessary.

5. Embryo-Fetal Toxicity: May be harmful to the fetus. Women of reproductive potential and men should use effective contraception during treatment and for a period of time following the last dose.

Drug Interactions

Strong CYP3A Inhibitors: Co-administration should be avoided; if co-administration is unavoidable, the dosage of repotrectinib must be reduced.

Strong CYP3A Inducers: Co-administration should be avoided, as these agents can significantly reduce repotrectinib plasma concentrations, thereby compromising efficacy.

CYP3A Substrates: Repotrectinib may increase the plasma concentrations of certain sensitive substrates (e.g., midazolam); caution should be exercised when co-administering these agents. Storage

Keep sealed in the original packaging; store at room temperature (20°C–25°C) and protect from moisture.